Cash from Investing (Quarterly) Chart

View Cash from Investing (Quarterly) for GBLX.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Cash from Investing (Quarterly) Chart
Start Trial

Historical Cash from Investing (Quarterly) Data

View and export this data back to 2001. Start Trial.
Date Value
December 31, 2024 0.00
September 30, 2024 0.00
June 30, 2024 0.00
March 31, 2024 0.00
December 31, 2023 0.085M
September 30, 2023 0.235M
June 30, 2023 0.00
March 31, 2023 0.00
December 31, 2022 -0.0013M
September 30, 2022 -0.0303M
June 30, 2022 0.00
March 31, 2022 -0.10M
December 31, 2021 1.449M
September 30, 2021 -0.0559M
June 30, 2021 0.1574M
March 31, 2021 0.0609M
December 31, 2020 3.997M
September 30, 2020 0.5977M
June 30, 2020 0.00
March 31, 2020 0.00
December 31, 2019 0.016M
September 30, 2019 -0.2971M
June 30, 2019 -0.2577M
March 31, 2019 -0.9049M
December 31, 2018 -1.884M
Date Value
September 30, 2018 -9.346M
June 30, 2018 1.138M
March 31, 2018 -0.9268M
December 31, 2017 -0.8289M
September 30, 2017 -0.4547M
June 30, 2017 -0.0731M
March 31, 2017 -2.133M
December 31, 2016 -0.9195M
September 30, 2016 0.0077M
June 30, 2016 -0.8225M
March 31, 2016 0.0998M
December 31, 2015 -0.0466M
September 30, 2015 -0.2298M
June 30, 2015 -0.2025M
March 31, 2015 -0.0075M
December 31, 2014 -0.5573M
September 30, 2014 -0.0685M
June 30, 2014 -0.0293M
March 31, 2014 -0.0152M
December 31, 2013 0.00
September 30, 2013 0.00
June 30, 2013 0.00
March 31, 2013 0.00
December 31, 2012 0.00
September 30, 2012 0.00

Cash From Investing Definition

Represents the net cash flow from the company's investing activities. Investing activities represent the movement in the company's long-term assets.

Read full definition.

Cash from Investing (Quarterly) Range, Past 5 Years

View Cash from Investing (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Cash from Investing (Quarterly) Benchmarks

View Cash from Investing (Quarterly) Benchmarks
Start Trial
Cocrystal Pharma, Inc. 0.00
CNBX Pharmaceuticals, Inc. 0.00
Arvinas, Inc. 54.90M
Fulcrum Therapeutics, Inc. 13.78M
Definium Therapeutics, Inc. -315.46M